New EPA rule could loosen limits on medical device sterilization gas emissions
medicalxpress - The U.S. Environmental Protection Agency (EPA) is proposing to loosen limits on emissions of ethylene oxide, a gas used to sterilize many medical devices that is also linked to cancer.
AI Summary: The Environmental Protection Agency proposed easing limits on ethylene oxide — the gas hospitals use to sterilize medical devices — arguing the change protects the medical supply chain. Public‑health experts and community advocates warn long‑term exposure raises cancer risks and say rolling back 2024 safeguards could shift the burden onto nearby residents.
Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma
esmo - Findings from the ZSAB-neoGOLP study
AI Summary: The ZSAB‑neoGOLP trial shows that giving a four‑drug neoadjuvant regimen—gemcitabine, oxaliplatin, lenvatinib and toripalimab—before surgery prolongs event‑free survival for patients with resectable, high‑risk intrahepatic cholangiocarcinoma. The finding suggests preoperative systemic therapy can downstage aggressive tumors and delay recurrence, potentially changing treatment sequencing for this challenging disease.
NRG-LU005 Trial: Atezolizumab Plus Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer
oncodaily - A major international clinical trial, NRG-LU005, has provided important new insight into how immunotherapy should be used in limited-stage small cell lung cancer (SCLC). While immune checkpoint inhibitors have significantly […]
AI Summary: A major international trial tested whether adding the PD‑L1 inhibitor atezolizumab to concurrent chemoradiotherapy for limited‑stage small‑cell lung cancer would boost outcomes. The study found no significant survival benefit, prompting clinicians to rethink the timing and role of immune checkpoint blockade in curative‑intent SCLC rather than assuming more drugs always means better results.
A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices
medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…
AI Summary: Researchers have identified HORMAD1, a normally reproductive‑cell gene, as a vulnerability in some triple‑negative breast cancers. Preclinical work suggests exploiting this target could guide patient selection and novel therapies, opening a promising — if early‑stage — route for a tumor type that desperately needs smarter options.
- HORMAD1: reproductive gene reveals vulnerability in triple‑negative breast cancer (3)
- New insights into why aggressive breast cancers grow and spread (3)
- OTHER: related cancer research and approvals outside this TNBC angle (5)
- All Other Stories
HORMAD1: reproductive gene reveals vulnerability in triple‑negative breast cancer
New insights into why aggressive breast cancers grow and spread
OTHER: related cancer research and approvals outside this TNBC angle
All Other Stories
Roche’s big hope breast cancer drug fails in crucial first-line trial
Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...
AI Summary: Roche’s experimental breast cancer oral agent failed to meet its primary endpoint in a pivotal first‑line trial, dashing expectations that it would become a major new therapy. The negative readout forces a strategic rethink for the program and raises questions about near‑term prospects for what had been touted as a potential blockbuster.
Fitch upgrades UCHealth’s rating to ‘AA+’
Andrew Cass / beckershospitalreview - Aurora, Colo.-based UCHealth’s credit rating was upgraded to “AA+” from “AA” by Fitch. The upgrade reflects the health system’s very strong financial profile, benefiting from its market position in a growing service area and a long track record of robust …
AI Summary: A large NHS evaluation found that an AI system can detect more invasive breast cancers than traditional reading alone, boosting detection by roughly 10%. The technology matched or rivaled radiologists in a major screening dataset, prompting debate about integration, workflow changes, and careful real-world rollout rather than unleashing bots in mammography rooms immediately.
- Mixed trial findings: AI triage not always noninferior. (1)
- NHS trial: AI boosts breast cancer detection by ~10%. (2)
- OTHER: AI in broader cardiac, hematology, imaging, and finance news. (4)
- Researchers and conferences push AI discussion in breast imaging. (2)
- All Other Stories
Mixed trial findings: AI triage not always noninferior.
NHS trial: AI boosts breast cancer detection by ~10%.
OTHER: AI in broader cardiac, hematology, imaging, and finance news.
Researchers and conferences push AI discussion in breast imaging.
All Other Stories
Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia
oncodaily - Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared a post by NEJM, […]
AI Summary: A global phase 3 trial shows romiplostim markedly reduces chemotherapy‑induced thrombocytopenia, cutting severe low‑platelet events and helping patients stay on planned treatment schedules. The finding promises to lower bleeding risk and avoid dose delays, a relief for clinicians and patients alike — and for anyone tired of rescheduled infusions.
Personalized Support Program Improves Smoking Cessation for Cervical Cancer Survivors – UCLA Health
oncodaily - UCLA study shows program doubles quit rates for women and offers a cost-effective approach A new study led by UCLA researchers suggests that a personalized counseling program can significantly help […]
AI Summary: A UCLA-led trial found that a tailored support program for women treated for cervical precancer significantly doubled smoking-cessation rates versus usual care. The intervention combined individualized counseling, follow-up, and survivor-focused resources, proving both clinically impactful and cost-effective — because apparently telling people to “just quit” still isn’t working.
Grail names new CEO as Bob Ragusa retires
Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...
AI Summary: Grail announced a leadership transition as long‑time chief executive Bob Ragusa retires and hands operational control to current president Josh Ofman. The move marks a new chapter for the cancer‑screening company as stakeholders watch for strategic shifts and commentary about the company’s unusual corporate journey and future direction.
Ipsen pulls cancer drug Tazverik from market over safety risks
Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...
AI Summary: Ipsen has removed its EZH2 inhibitor Tazverik (tazemetostat) from the U.S. market after safety issues flagged by an independent monitoring review. The withdrawal forces clinicians to pivot to alternative therapies and triggers regulatory and clinical re‑examination of the drug’s benefit‑risk profile for patients previously depending on it.
Severe COVID or Severe Flu May Raise Risk of Lung Cancer, But Vaccines Helped in Animal Tests
discovermagazine - Learn how severe respiratory illness leaves the lungs vulnerable to cancer, and how vaccines could prevent these vulnerabilities.
AI Summary: New animal and observational evidence suggests severe respiratory infections—including serious COVID‑19 and influenza—can prime lung tissue and accelerate cancer development months to years later. Vaccination appeared to blunt those effects in experimental models, highlighting prevention as a potential cancer‑risk reduction strategy and urging clinicians to watch survivors of severe infections more closely.
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors
Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga / science - Science Translational Medicine, Volume 18, Issue 839, March 2026.
AI Summary: Researchers engineered CAR‑T cells to secrete VEGF‑neutralizing single‑chain antibodies, improving infiltration and antitumor activity against solid tumors in preclinical models. By locally neutralizing VEGF, the approach remodels the tumor microenvironment and enhances CAR‑T efficacy, offering a plausible strategy to overcome the long‑standing barrier of poor CAR‑T performance in solid cancers.
Elizabeth McKenna: New Cancer Grand Challenges Teams Announced
oncodaily - Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X: “The new Cancer Grand Challenges teams have just been announced! Read about the teams tackling cancer avoidance, mechanisms […]
AI Summary: Global funders announced new Cancer Grand Challenges awards, backing five international teams with large, high‑risk grants to pursue transformative cancer science. The initiative aims to accelerate unconventional, high‑reward projects and foster cross‑disciplinary collaboration — essentially underwriting audacity in hopes that at least one risky bet pays off.
ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS
oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]
AI Summary: At ASCO GU, investigators showcased belzutifan‑based combinations for renal cell carcinoma, including belzutifan with lenvatinib and perioperative belzutifan plus pembrolizumab. Data presented indicate these HIF‑2α‑targeted regimens can extend disease‑free intervals in high‑risk clear‑cell RCC, prompting interest in integrating hypoxia‑axis inhibitors into multimodal kidney‑cancer care.
New AI tool predicts best pancreatic cancer treatment
medicalxpress - A new tool co-developed by investigators from Cedars-Sinai Health Sciences University can predict which of two available chemotherapy options for pancreatic cancer would be more effective for an individual patient.
AI Summary: A Cedars‑Sinai–developed AI platform predicts which of two standard chemotherapy regimens will best suit individual pancreatic cancer patients. The model analyzes clinical and molecular data to guide therapy selection, aiming to personalize treatment and improve outcomes in a disease notorious for poor prognosis—because guesswork is overrated when lives are at stake.
Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma
Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…
AI Summary: Servier is buying Day One Biopharmaceuticals for about $2.5 billion to bolster its rare oncology portfolio, gaining access to promising targeted therapies. The deal expands Servier’s presence in specialty cancer medicines and aligns with its strategic push into rare tumors, with integration and regulatory steps expected to follow.
Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less
esmo - Findings from the POSEIDON meta-analysis of the MARCAP consortium
AI Summary: A pooled POSEIDON meta-analysis from the MARCAP consortium found that adding androgen-deprivation therapy to post‑operative radiotherapy for recurrent prostate cancer with PSA ≤0.5 ng/mL does not improve outcomes meaningfully. In short: the extra hormonal punch may not be worth the side effects many patients will endure.
Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours
esmo - Findings from the PYNNACLE study
AI Summary: Clinical results from the PYNNACLE program demonstrate that rezatapopt, an oral small‑molecule p53 reactivator, produces antitumor activity in cancers driven by the TP53 Y220C mutation. Early data validate targeting a previously “undruggable” p53 variant, offering a concrete therapeutic strategy and sparking excitement — and a few warranted caveats — about broader applicability.
Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears
oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]
AI Summary: Merck reorganized its Human Health structure to form a separate oncology business unit, positioning the company to defend and optimize its cancer franchise ahead of Keytruda patent pressures and to sharpen focus across therapeutic areas as part of a broader commercial realignment.
Microplastics discovered in prostate tumors
medicalxpress - Small fragments of plastic were found in 9 out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, a new study finds. The small, single-center study was led by researchers at NYU Langone Health, its …
AI Summary: Researchers report finding microplastic fragments in the vast majority of examined prostate tumor samples, at higher levels than surrounding noncancerous tissue. The study raises uneasy questions about environmental contaminants accumulating in human tissues and their potential interactions with cancer biology, though causation remains unproven and further research is clearly overdue.